Leading in MPNs Beyond Ruxolitinib in Combo With T-Regs

Phase 1

Recruiting

• Conditions: Myelofibrosis
• Interventions: Drug: CK0804

• Registration Number: NCT05423691
• Lead Sponsor: Cellenkos, Inc.

Brief Summary

To assess the safety and tolerability of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Detailed Description

1. Safety Run-in

The study will employ a 3+3+3 design to assess the safety and tolerability of the treatment based on treatment-limiting toxicities (TLTs) occurring up to 1 Cycle (28 days) after the first infusion.

2. Expansion

After a total of 9 participants completed 28 days and are evaluated for tolerability in the safety run-in phase, additional participants may be included in the expansion cohort in order to have approximately 24 evaluable myelofibrosis

Study Timeline

• Study First Submitted: 2022-06-10
• Study First Submitted QC: 2022-06-15
• Study First Posted: 2022-06-21
• Study Start: 2022-12-27
• Status Verified: 2025-04
• Last Update Submitted: 2025-04-10
• Last Update Posted: 2025-04-13
• Primary Completion: 2026-04-30
• Study Completion: 2026-12-30

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 24

Inclusion Criteria

1. Ability to comprehend and willingness to sign a written informed consent form (ICF) for the study.

2. Age above 18 years inclusive at the time of signing the ICF.

3. Participants who fulfill the diagnostic criteria of myelofibrosis including primary myelofibrosis and myelofibrosis arising from polycythemia vera and essential thrombocythemia

4. Life expectancy is greater than 6 months.

5. Subject has been receiving ruxolitinib therapy, is unlikely to benefit from further ruxolitinib monotherapy in the opinion of the investigator; AND meeting the following criteria: receiving ruxolitinib >3 months prior to enrollment; AND stable dose for 8 weeks before starting therapy with CK0804

6. Subject with evidence of evaluable residual burden of disease following ruxolitinib monotherapy treatment, consisting of:

   • presence of grade ≥2 anemia or thrombocytopenia or neutropenia, OR
   • presence of disease-related symptoms, as determined by a Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN SAF TSS) score of ≥10 points, OR
   • documented splenomegaly of at least 5 cm below the costal margin as measured by physical examination or splenomegaly as documented by ultrasound or MRI.

7. Willingness to avoid pregnancy or fathering children based on the criteria below

   • Men must agree to take appropriate precautions to avoid fathering children (with at least 99% certainty) from screening through 90 days after the last study treatment dose and must refrain from donating sperm during this period. Permitted methods that are at least 99% effective in preventing should be communicated to the participants and their understanding confirmed.
   • Women of childbearing potential must have a negative serum pregnancy test at screening before the first dose (within 3 days of the first study treatment dose) and must agree to take appropriate precautions to avoid pregnancy (with at least 99% certainty) from screening through the safety follow-up visit and must not donate oocytes during this period. Permitted methods that are at least 99% effective in preventing pregnancy should be communicated to the participants and their understanding confirmed,
   • Women of nonchildbearing potential (ie, surgically sterile with a hysterectomy and/or bilateral oophorectomy OR ≥ 12 months of amenorrhea and at least 50 years of age) are eligible.

8. ECOG performance status of 0 to 2

Exclusion Criteria

1. Any major surgery within 28 days before the first dose of study treatment.

2. Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation.

3. Received chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment.

4. Participant has received splenic irradiation within the past 6 months.

5. Significant concurrent, uncontrolled medical condition or infections, which in the opinion of the principal investigator may interfere in the study participation.

6. Inability or unlikeliness of the participant to comply with the dose schedule and study evaluations, in the opinion of the investigator.

7. Women who are pregnant or breastfeeding.

8. Any condition that would, in the investigator's judgment, interfere with full participation in the study, including administration of study treatment and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data.

9. Participants with laboratory values at screening as defined

   • Platelets < 50 × 10^9/L without the assistance of growth factors, thrombopoietic factors, or platelet transfusions
   • ANC < 0.5 × 10^9/L
   • ALT ≥ 2.5 × ULN
   • AST ≥ 2.5 × ULN
   • Direct Bilirubin > 2.0 × ULN
   • ALP ≥ 3 × ULN
   • Creatinine clearance < 50 mL/min according to Cockcroft-Gault formula.

10. Unwillingness to be transfused with blood components including RBC and platelet transfusions.

11. Inability of the participant (or parent, guardian, or legally authorized representative) to comprehend the ICF or unwillingness to sign the ICF.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Arm 1	CK0804	CK0804 will be administered intravenously (IV) 100 million Treg Cells every 28 days up to 6 infusions.

Primary Outcome Measures

Name	Time	Method
To determine Treatment limiting toxicity (TLT) as defined below	28 days	* severe (grade 3 or 4) infusion-related toxicity within 24 hours (NCI-CTCAE V5.0) of exposure that does not resolve with standard of care treatment within 72 hours.; * regimen related death within 28 days

Secondary Outcome Measures

Name	Time	Method
Assessment of overall response rate (ORR) (measured as CR or PR) and its duration, using modified International Working Group-Myeloproliferative Neoplasm Research and Treatment (IWG-MRT) and European Leukemia Net (ELN) consensus report.	6 months	To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Rate of anemia response as per modified IWG-MRT ELN response criteria.	6 months	To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Rate of spleen response by imaging at and after 24 weeks as per IWG-MRT ELN response criteria	6 months	To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib
Percentage of Participants who will Achieve Total Symptom Score Reduction Greater Than or Equal to (≥) 50% (TSS50) as Measured by Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)	6 months	To determine the efficacy of CK0804 as add-on therapy in participants with myelofibrosis, with suboptimal response to ruxolitinib

Trial Locations

Locations (4)

UC Davis Health; 🇺🇸 Sacramento, California, United States

Montefiore Einstein Cancer Center; 🇺🇸 Bronx, New York, United States

Columbia University; 🇺🇸 New York, New York, United States

The University of Texas MD Anderson Cancer Center; 🇺🇸 Houston, Texas, United States